ONCONASE

Related by string. Onconase * * leopard frog ONCONASE . ONCONASE triggers apoptosis . ONCONASE R . ONCONASE ranpirnase *

Related by context. All words. (Click for frequent words.) 69 Onconase 68 ONCONASE R 67 Virulizin ® 67 Virulizin R 67 IMA# 67 obatoclax 67 oral ridaforolimus 67 vosaroxin 67 ganetespib 67 tanespimycin 66 EndoTAG TM -1 66 torezolid phosphate 66 Azedra 66 Traficet EN 66 Phase #b/#a clinical 66 oral prodrug 66 Fibrillex TM 66 forodesine 66 DXL# 66 AEG# 66 OvaRex R 65 alvimopan 65 Archexin 65 PRT# 65 PXD# 65 Tyrima 65 amrubicin 65 MGCD# [001] 65 vidofludimus 65 OHR/AVR# 65 Allovectin 7 R 65 registrational 65 Xanafide 65 Civacir 65 OncoVEX GM CSF 65 Symadex 65 ospemifene 65 Amrubicin 65 phase IIb clinical 64 INCB# [001] 64 CBLC# 64 HGS ETR1 64 alvespimycin 64 YONDELIS 64 Cloretazine ® 64 talactoferrin 64 liposomal formulation 64 SNT MC# 64 depsipeptide 64 PLK1 SNALP 64 anticancer agent 64 Amplimexon 64 Marqibo 64 atacicept 64 Bezielle 64 Icatibant 64 CINTREDEKIN BESUDOTOX 64 LibiGel ® 64 OMAPRO 64 ALN TTR 64 CoFactor 64 Cethromycin 64 OvaRex ® MAb 64 cancer immunotherapies 64 HuMax CD4 64 CCX# 63 Myocet 63 HGS# 63 #D#C# 63 phase IIa clinical 63 CA4P 63 eniluracil 63 HuMax EGFr 63 ProLindac TM 63 Neuradiab 63 BEXXAR 63 EOquin TM 63 Onalta 63 CEQ# 63 PREOS R 63 Omacetaxine 63 Dyloject TM 63 INT# [002] 63 AP# [003] 63 deforolimus 63 Panzem R NCD 63 CIMZIA ™ 63 Phase Ib 63 orally bioavailable 63 Aflibercept 63 anticancer compound 63 Cloretazine R VNP#M 63 elotuzumab 63 Phase 2a trial 63 Serdaxin 63 otelixizumab 63 ZOLINZA 63 Phenoptin 63 eltrombopag 63 PSN# [002] 63 XmAb# 63 Urocidin 63 PEG SN# 63 ADAGIO study 63 Aplidin 63 Phase IIIb clinical 63 investigational humanized monoclonal antibody 63 MAGE A3 ASCI 63 AQ4N 63 MT#/MEDI-# 63 Tamibarotene 63 thymalfasin 63 MOZOBIL 63 leading oral taxane 63 AA amyloidosis 63 TREANDA 62 Ostarine 62 NEUMUNE 62 proteasome inhibitor 62 Alfacell 62 Alpharadin 62 UPLYSO 62 Panzem 62 FOLOTYN ® 62 Alocrest 62 romidepsin 62 IMGN# 62 tezampanel 62 Bortezomib 62 Phase Ib II 62 PRTX 62 palifosfamide 62 KIACTA ™ 62 DAVANAT R 62 Stedivaze 62 PDE4 inhibitor 62 Fodosine 62 axitinib 62 fidaxomicin 62 PREOS 62 Valortim 62 Trofex 62 Quinamed 62 Bicifadine 62 PSMA ADC 62 Exherin TM 62 Sym# 62 SAR# [004] 62 TOCOSOL Paclitaxel 62 Anticalin R 62 PANVAC VF 62 targeted radiotherapeutic 62 PROVENGE sipuleucel T 62 Pralatrexate 62 KNS # 62 Aurexis 62 JAK inhibitor 62 radiation sensitizer 62 tramiprosate 62 pomalidomide 62 carfilzomib 62 CR# vcMMAE 62 volociximab 62 targeting CD# 62 vascular disrupting agent 62 CCR9 antagonist 62 Protexia ® 62 Epratuzumab 62 R#/MEM # 62 Ophena TM 62 humanized anti 62 Perifosine 62 Panzem R 62 PEG Interferon lambda 62 BioNumerik 62 Solazed 62 Zenvia ™ 62 entinostat 62 diarrhea predominant irritable 62 tamibarotene 62 HuLuc# 62 Tezampanel 62 Lixivaptan 62 ZK EPO 62 TELINTRA 62 BAY #-# 62 Ruconest 62 OXi# 61 Nanobody 61 Genz # 61 TG# [003] 61 IND submission 61 castration resistant prostate cancer 61 Cloretazine R 61 ATL# [001] 61 Phase 2b Clinical Trial 61 HQK 61 MYDICAR ® 61 novel histone deacetylase 61 L BLP# 61 MORAb 61 Carfilzomib 61 maribavir 61 NEBIDO 61 CYC# 61 HGS ETR2 61 AEGR 61 HuMax CD# 61 LymphoStat B 61 MEK inhibitors 61 Allovectin 7 61 Anavex #-# 61 PNP inhibitor 61 lintuzumab 61 MabCampath 61 MNTX 61 reslizumab 61 Hsp# inhibitor 61 Abiraterone acetate 61 favorable pharmacokinetic profile 61 Romidepsin 61 Dapagliflozin 61 anticoagulant reversing agent 61 ALN PCS 61 OncoVEX 61 registrational trial 61 Phase IIB 61 Pimavanserin 61 BLA submission 61 Proxinium TM 61 pan HDAC inhibitor 61 clofarabine 61 metaglidasen 61 OPAXIO 61 refractory gout 61 Azedra TM 61 ENMD # 61 BEMA TM Fentanyl 61 Firazyr 61 tafamidis 61 MGd 61 DOS# 61 diabetic neuropathic pain 61 Pirfenidone 61 ELACYT 61 Loramyc R 61 Diamyd ® 61 Phase Ib study 61 Cloretazine 61 Factor VIIa 61 RIGScan CR 61 DAVANAT ® 61 lomitapide 61 Orazol 61 Catena ® 61 Ceflatonin R 61 ProLindac 61 Mipomersen 61 tezampanel NGX# 61 trodusquemine 61 TriRima 61 Vandetanib 61 Celator 61 severe gastroparesis 61 ixabepilone 61 LE DT 61 lorvotuzumab mertansine 61 EFAPROXYN 61 Leukine 61 Thiarabine 61 Tarvacin 61 subcutaneous formulation 61 RNAi therapeutic targeting 61 EOquin 61 rxRNA 61 Dextofisopam 61 YONDELIS R 61 Phase 1b trial 61 antibody MAb 61 picoplatin 61 teduglutide 61 cintredekin besudotox 61 cethromycin 61 NGX# 61 Seliciclib 61 Zensana TM 61 ularitide 61 CCX# B 61 castrate resistant prostate cancer 61 custirsen 61 Evoltra ® 61 Trastuzumab 61 NDA submission 61 ASONEP 61 DAVANAT 61 MAA submission 60 phase IIb trial 60 faropenem 60 Tarceva TM 60 OMNARIS HFA 60 pseudobulbar affect PBA 60 omega interferon 60 Vidofludimus 60 IL# PE#QQR 60 CLORETAZINE TM VNP#M 60 MEK inhibitor RDEA# 60 therapeutic monoclonal antibody 60 Alzhemed TM 60 ONTAK 60 NP2 Enkephalin 60 Xcytrin R 60 PD LID 60 Phase IIb clinical trials 60 MAXY G# 60 GAP #B# 60 CCR5 antagonist 60 ALN VSP 60 Vicinium TM 60 ACOMPLIA R 60 Phase IIa trials 60 NXL# 60 TRO# 60 sorafenib Nexavar 60 PCK# 60 acyclovir Lauriad R 60 Elagolix 60 Ambrisentan 60 samalizumab 60 cell lymphoma CTCL 60 pralatrexate 60 cystinosis patients 60 relapsed multiple myeloma 60 velafermin belinostat 60 AeroLEF TM 60 TBC# 60 Golimumab 60 KRN# 60 Cetrorelix 60 Anthim 60 pharmacokinetic PK study 60 investigational pan BCR 60 Meets Primary Endpoint 60 IIa trial 60 linaclotide 60 SinuNase 60 PI3K/Akt pathway inhibitor 60 huC# DM4 60 Tavocept 60 canakinumab 60 Fibrin Pad 60 systemically administered 60 pertuzumab 60 ADVEXIN 60 rFVIIIFc 60 Belinostat 60 Exelixis XL# 60 investigational therapies 60 relapsed MM 60 Zingo TM 60 lumiliximab 60 ARIKACE ™ 60 novel oral anticoagulant 60 CRMD# 60 fosbretabulin 60 NDA resubmission 60 bafetinib 60 GED aPC 60 Dalbavancin 60 StaphVAX R 60 Ceflatonin 60 LHRH antagonist 60 preclinical toxicology 60 omacetaxine 60 Chrysalin 60 vorinostat 60 Kuvan R 60 Anturol TM 60 Tarvacin TM 60 Aplidin R 60 GFT# 60 MEK inhibitor 60 Hsp# Inhibitor 60 siRNA therapeutics 60 rNAPc2 60 Phase #/#a trial 60 preclinically 60 octreotide implant 60 Proellex TM 60 AzaSite Plus 60 Angiocept 60 rindopepimut 60 Glybera R 60 Personalized Immunotherapy 60 Telatinib 60 Octreolin 60 enzastaurin 60 nucleoside analog 60 OMP designation 60 cMET 60 ZYBRESTAT 60 Epanova 60 rilonacept 60 HCV protease inhibitors 60 Nexavar ® 60 Cerashield 60 Corlux 60 satraplatin 60 Capesaris 60 EndoTAG TM 60 Clolar ® 60 CRD5 60 Phase IIb clinical 60 orBec 60 TYZEKA 60 Biologics License Application 60 investigational drug 60 abiraterone acetate 60 tolevamer 60 SCCHN 60 Nasulin 60 Taxotere ® 60 Ketotransdel 60 histone deacetylase inhibitor 60 BLA filing 60 paclitaxel Taxol R 60 preclinical efficacy 60 Cardio Vascu Grow 60 ridaforolimus 60 rFIXFc 60 dexpramipexole 60 angiogenesis inhibitor 60 Cintredekin Besudotox 60 Plicera 60 Aclidinium 60 Raptiva ® 59 Triolex 59 Fast Track designation 59 GLP toxicology studies 59 cilengitide 59 REP# 59 TRV# [001] 59 drug ISA# 59 brivaracetam 59 Ophena 59 cutaneous T 59 IRX 2 59 DR Cysteamine 59 orally administered inhibitor 59 EDEMA3 59 Ridaforolimus 59 mapatumumab 59 GRN#L 59 ancrod 59 voreloxin 59 Fortical R 59 BNC# 59 Saforis 59 Chemophase 59 ISTODAX 59 pain palliation 59 glufosfamide 59 Insegia 59 paclitaxel Taxol ® 59 perifosine 59 incyclinide 59 demonstrated antitumor activity 59 silodosin 59 crofelemer 59 alkylating agent 59 Cinryze ™ 59 CYT# potent vascular disrupting 59 Clavis Pharma 59 selective androgen receptor modulator 59 Pivotal Phase III 59 PHX# 59 apoptosis inducer 59 LEUKINE 59 oral taxane 59 Memryte 59 ZADAXIN ® 59 Phase Ib clinical 59 Asentar 59 THR beta agonist 59 LEP ETU 59 Anturol 59 XYOTAX TM 59 elagolix 59 TKM ApoB 59 MT# MEDI 59 Lenocta 59 lucinactant 59 GAMMAGARD 59 LE SN# 59 successfully commercialize Iluvien 59 Elesclomol 59 HspE7 59 delafloxacin 59 ELND# 59 docetaxel Taxotere R 59 Annamycin 59 Biologics License Application BLA 59 Opexa 59 StemEx R 59 CD# antibody [001] 59 Amigal 59 GLYX 59 intranasal formulation 59 tocilizumab 59 immunotherapeutic vaccine 59 Neulasta R 59 personalized immunotherapy 59 Gefitinib 59 MyVax R 59 Pemetrexed 59 StemEx 59 cariprazine 59 TELCYTA 59 HER2 positive metastatic breast 59 ocular formulation 59 Onco TCS 59 BrachySil TM 59 DU #b 59 CD# monoclonal antibody 59 EchoCRT 59 hematological cancers 59 Genasense ® 59 trastuzumab DM1 T DM1 59 anti EGFR antibody 59 androgen independent 59 ARIKACE 59 virus HCV protease inhibitor 59 Panitumumab 59 riociguat 59 ofatumumab HuMax CD# 59 Phase 1b 59 Fx #A 59 OMP #M# 59 Pradefovir 59 tiapamil 59 Phase 1a clinical 59 sapacitabine 59 Tanespimycin 59 ATryn R 59 Glufosfamide 59 Tasimelteon 59 ACZ# 59 antiplatelet agent 59 Orphan Drug designations 59 lenalidomide Revlimid R 59 Talabostat 59 R roscovitine 59 HCV protease 59 candidate Zenvia 59 confirmatory clinical 59 zanolimumab 59 ILUVIEN ® 59 vilazodone 59 Arcalyst 59 Gabapentin GR 59 bevacizumab Avastin ® 59 pitavastatin 59 Telintra 59 Phase IIb trials 59 Surfaxin LS 59 LUVENIQ 59 ulimorelin 59 Inhalation Solution 59 Exelixis compounds 59 SCH # 59 DCVax ® 59 erlotinib Tarceva ® 59 Clofarabine 59 phase Ib 59 Voreloxin 59 LEVADEX 59 Sulonex TM 59 Ramoplanin 59 MEK Inhibitor 59 Phase III Pivotal 59 Urokinase 59 Irinotecan 59 PEG PAL 59 BRAF inhibitor 59 NEUGENE 59 HCV protease inhibitor 59 ProSavin 59 Zybrestat 59 VALSTAR 59 velafermin 59 huN# DM1 59 TPI ASM8 59 CD3 monoclonal antibody 59 Telaprevir 59 Zerenex 59 receptor tyrosine kinase inhibitor 59 ataluren 59 tranilast 59 defensin mimetic antibiotic 59 ATL# [002] 59 Belimumab 59 THALOMID 59 Harbor BioSciences 59 mGluR5 NAM 59 AZX# 59 Synavive 59 Soliris TM eculizumab 59 IMC A# 59 Vilazodone 59 Daclizumab 59 Fidaxomicin 59 Microplasmin 59 selective kinase inhibitor 59 metastatic hormone refractory 59 Phase 2a clinical trials 59 Solazed TM 59 ApoB SNALP 59 bardoxolone 59 JAK inhibitors 59 PDX pralatrexate 59 lapatinib Tykerb 59 Tesetaxel 59 Targretin 59 MKC# MKC# PP 59 unresectable malignant mesothelioma UMM 59 Velcade bortezomib 59 Vascular Wrap TM 59 Zolinza 59 ALN TTR# 59 Kevetrin 59 BZL# 59 PROMACTA 59 Neurodex 59 IAP inhibitors 59 RhuDex ® 59 BRIM2 59 BRIM3 59 confirmatory Phase 3 59 Evoltra R 59 PEGylated interferon beta 1a 59 Zelrix 59 investigational HCV polymerase 59 delivers fluocinolone acetonide FA 59 EDEMA3 trial 59 Manja Bouman CEO 59 UVIDEM 59 Cinryze TM 59 dirucotide 59 methylnaltrexone 59 Curaxin 59 durable remissions 59 cangrelor 59 Dacogen injection 59 Phase IIa trial 59 EVIZON TM 59 opioid induced bowel dysfunction 59 cutaneous T cell 59 liprotamase 59 BYETTA ® 59 Evoltra TM 59 TOLAMBA 59 Davanat 59 Hsp# inhibition 59 phase IIa 59 Pennsaid R 59 thalidomide Thalomid 59 sargramostim 58 refractory chronic lymphocytic 58 ruxolitinib 58 Soliris eculizumab 58 MDV# 58 Apoptone 58 Phenserine 58 seliciclib CYC# 58 BCX# 58 PGL# 58 mitogen activated ERK kinase 58 DermaVir Patch 58 Protexia R 58 Veronate 58 zalutumumab 58 OMNARIS Nasal Spray 58 Sapacitabine 58 Xerecept 58 oral picoplatin 58 cannabinor 58 histone deacetylase HDAC inhibitor 58 sunitinib malate 58 elesclomol 58 epothilone 58 RAV# 58 Desmoteplase 58 Aviptadil 58 mertansine 58 Triapine 58 INCB# [002] 58 Octreotide 58 FavId 58 generation purine nucleoside 58 NVA# 58 orphan designation 58 Campath ® 58 Phase 2b study 58 pharmacokinetic PK 58 CANCIDAS 58 CORLUX 58 sorafenib tablets 58 oral FTY# 58 ALGRX 58 Anturol ® 58 Zoraxel 58 AeroLEF 58 StaphVAX 58 PrevOnco ™ 58 Imprime PGG 58 RhuDex 58 daclizumab 58 Prestara 58 epothilones 58 ProMune 58 methylnaltrexone bromide 58 Enzyme Replacement Therapy 58 Indaflex TM 58 acetonide FA 58 Satraplatin 58 DDP# 58 PS# [001] 58 Gleevec resistant 58 rALLy trial 58 ASA# 58 antitumor activity 58 GW# [003] 58 Diabetic Macular Edema 58 Kamada AAT 58 Intravenous CP 58 superficial bladder cancer 58 RGB # 58 AVN# [001] 58 dextofisopam 58 mTOR inhibitor 58 Resten NG 58 CB2 selective receptor agonist 58 Advexin 58 Locteron ® 58 heavily pretreated 58 Locteron 58 RDEA# 58 phase IIb study 58 IRESSA 58 hematological malignancies 58 refractory Hodgkin lymphoma 58 CIMZIA TM 58 Evoltra 58 CDK inhibitor 58 ORE# 58 histamine dihydrochloride 58 AZILECT ® 58 mRCC 58 valopicitabine 58 metastatic sarcomas 58 ISIS # 58 postoperative ileus 58 PRX# 58 Cutaneous T 58 Restanza 58 tesmilifene 58 talabostat 58 oral deforolimus 58 BENLYSTA 58 GRN# 58 AZILECT R 58 Menerba 58 vascular disrupting agents 58 Excellarate TM 58 humanized monoclonal antibody 58 BLP# Liposome Vaccine 58 CTAP# Capsules 58 Blinatumomab 58 Hematide ™ 58 Bendamustine 58 ICA # 58 ARRY # 58 ALN RSV# 58 CCR5 mAb 58 oral anticoagulant 58 PROVENGE ® 58 ambrisentan 58 Cannabinor 58 Vernakalant 58 Pertuzumab 58 SUCCEED trial 58 oral proteasome inhibitor 58 Bioral Amphotericin B 58 Phase III Clinical Trial 58 Bioral ® 58 6R BH4 58 Acute Radiation Syndrome ARS 58 GRNVAC1 58 pediatric acute lymphoblastic 58 Emezine 58 temsirolimus 58 placebo controlled clinical 58 EndoTAGTM 1 58 Sudhir Agrawal D.Phil 58 dacetuzumab 58 Entereg R 58 Maribavir 58 vemurafenib 58 RNAi Therapeutic 58 ofatumumab 58 PROVENGE 58 Dacogen decitabine 58 Fibrillex 58 trabectedin 58 Mepact 58 Allovectin 7 ® 58 Onalta ™ 58 Aliskiren 58 Bendavia 58 ONSOLIS 58 Leukine ® 58 VEGF Trap 58 ponatinib 58 LY# [003] 58 OMP #R# 58 candidate deforolimus 58 Fabry Disease 58 hypoxia activated prodrug 58 regorafenib 58 Loramyc 58 cathepsin K inhibitor 58 Onrigin 58 Valdoxan 58 pharmacological chaperone 58 Varespladib 58 Homspera 58 immatics 58 Cytolin ® 58 Friedreich Ataxia FRDA 58 luliconazole 58 CRLX# 58 Combidex 58 hyaluronidase enzyme 58 davunetide intranasal AL 58 Ozarelix 58 APF# 58 OncoGel 58 ATL/TV# 58 cGMP manufacture 58 HCD# [002] 58 MYDICAR 58 relapsed refractory multiple myeloma 58 Troxatyl 58 Aganocide 58 Theratope 58 Linaclotide 58 Dasatinib 58 Cethrin 58 ongoing Phase 1b 58 autologous cellular immunotherapy 58 MAP# 58 investigational monoclonal antibody 58 adult chronic ITP 58 Phase 1b clinical 58 Pazopanib 58 PROSTVAC TM 58 p# inhibitor 58 PNT# 58 AAG geldanamycin analog 58 Serdaxin ® 58 Pivotal Trial 58 eprotirome 58 AACR NCI EORTC 58 generation Hsp# inhibitor 58 oritavancin 58 NO# [002] 58 SparVax TM 58 Phase III clinical 58 Plenaxis TM 58 laquinimod 58 Reverset 58 TACI Ig 58 triphendiol 58 Viramidine 58 Dendreon Provenge 58 biologic therapies 58 dosing cohort 58 NNR Therapeutics 58 erlotinib Tarceva 58 non nucleoside 58 BrachySil 58 HRPC 58 TRISENOX 58 QNEXA 58 Orphan Status 58 prucalopride 58 acyclovir Lauriad ® 58 Abiraterone 58 IMP# 58 NV1FGF 58 Phase 1b clinical trials 58 JAK1 58 GTC recombinant human 58 Androxal ® 58 motexafin gadolinium Injection 58 afatinib 58 personalized cellular immunotherapy 58 ADVANCE PD 58 ADP receptor antagonist 58 adecatumumab 58 Nanobody ® 57 TKM PLK1 57 WILEX 57 oncology indications 57 isoform selective 57 omacetaxine mepesuccinate 57 rhThrombin 57 cetuximab Erbitux ® 57 inhaled liposomal ciprofloxacin 57 HSP# inhibitor 57 trastuzumab Herceptin R 57 dalbavancin 57 candidates bavituximab 57 BiTE antibody 57 metastatic castration resistant 57 Aurora kinase 57 herpetic keratitis 57 TroVax ® 57 NDA Submission 57 non nucleoside inhibitor 57 bortezomib Velcade ® 57 liposomal doxorubicin 57 proteasome inhibitors 57 EGS# 57 Ereska 57 zileuton 57 VitiGam 57 lixivaptan 57 Cethrin R 57 Ceragenix 57 phase IIb III 57 tesetaxel 57 RNAi therapeutic 57 prGCD 57 Prodarsan R 57 bendamustine HCl 57 viral kinetic 57 nalbuphine ER 57 Riquent 57 IMiDs R 57 immunotherapeutic agent 57 APOPTONE 57 Lucanix R 57 Phase #b/#a 57 C1 INH 57 crizotinib PF # 57 imatinib mesylate Gleevec 57 bosutinib 57 Naproxcinod 57 darapladib 57 Rhucin ® 57 RECOTHROM R 57 Actimmune ® 57 metastatic HRPC 57 Phase 2b trial 57 adipiplon 57 FRDA 57 QLT# 57 MoxDuo IR 57 Phase IIb Clinical Trial 57 Zerenex ™ 57 including eniluracil ADH 57 Phase 2a clinical 57 TRX1 57 phase IIb 57 multicenter Phase III 57 epratuzumab 57 Orphan Drug status 57 Presents Preclinical Data 57 REG1 Anticoagulation System 57 lymphoid malignancies 57 telomerase therapeutic 57 palonosetron 57 PEGPH# 57 trastuzumab DM1 57 mesylate 57 oxypurinol 57 HDAC Inhibitor 57 Anaphore 57 TLK# 57 FOLOTYN 57 rALLy clinical trial 57 teriflunomide 57 PEGylated Fab fragment 57 Atiprimod 57 Guanilib 57 iniparib 57 Uvidem 57 Curaxin CBLC# 57 edoxaban

Back to home page